Subir Basak, Ph.D., MBA
Dr. Basak is an accomplished technical and management expert in Biotechnology, Pharma, Health and Medtech and has been an entrepreneur since 2015. He has spent 20+ years in roles of increasing responsibility from Merck Fellow in R&D, Production Management, Regulatory Affairs, General Management, and CEO/President roles. He has been the Whole-time Director to Jubilant, Intas and the Board Member of Aragen in the US. He has also been the Managing Director of El-Lilly Joint Venture Vanthys. He is a TIE Charter Member and has worked with many pharma and biotech companies and has successfully conducted scores of technical due diligence, plant audits and visits, Process development, scale-up, Troubleshooting for R&D and Production, Tech transfer, CMC strategy and execution, and US FDA remediation work with B2B Clients. He is currently serving as a WHO taskforce Member for Covid-response and also on the Global Steering Committee for Pharma security involving several multilateral organizations.
Dr. Basak was the President at Jubilant Life Sciences (JDDS - subsidiary) and Chief Executive Officer and Head at Intas BioPharma and Dr Reddys Laboratories. He had direct P&L responsibility and managed 1600 employee businesses encompassing R&D, Production, Supply Chain, Quality, Corp Development, Business Development, R&D, Manufacturing, and Commercial Operations. Prior to working in Asia-Pac, he worked in the US for Amgen, Merck, and Bayer Pharmaceuticals. He received a M.S and Ph.D. in Biochemical Engineering from Purdue University (USA), MBA from the Kellogg School of Management (Northwestern University, USA), and B.E. in Chemical Engineering from the Indian Institute of Technology (INDIA). He has done advanced management programs at the Harvard Business School and the Wharton School (University of Pennsylvania).